The bench described the proposed increase as “reasonable” and consistent with the court’s original intent.

Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.

European football has rescued dicey domestic seasons for Liverpool before. Perhaps it still will in what remains of 2025-26 but as Bruce Springsteen prophesied, you can’t start a fire without a spark.

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026Zipalertinib rolling NDA ...